Cotinga Pharmaceuticals Competitors

Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Volatility & Risk

Acerus Pharmaceuticals has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, indicating that its stock price is 4,244% more volatile than the S&P 500.

Profitability

This table compares Acerus Pharmaceuticals and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

0.0% of Acerus Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Acerus Pharmaceuticals and Cotinga Pharmaceuticals, as provided by MarketBeat.

Earnings & Valuation

This table compares Acerus Pharmaceuticals and Cotinga Pharmaceuticals' gross revenue, earnings per share and valuation.

Cotinga Pharmaceuticals has lower revenue, but higher earnings than Acerus Pharmaceuticals.

Summary

Cotinga Pharmaceuticals beats Acerus Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

American Bio Medica (OTCMKTS:ABMC) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for American Bio Medica and Cotinga Pharmaceuticals, as provided by MarketBeat.com.

Earnings & Valuation

This table compares American Bio Medica and Cotinga Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

American Bio Medica has higher revenue and earnings than Cotinga Pharmaceuticals.

Risk and Volatility

American Bio Medica has a beta of -1.45, suggesting that its stock price is 245% less volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, suggesting that its stock price is 4,244% more volatile than the S&P 500.

Profitability

This table compares American Bio Medica and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Cotinga Pharmaceuticals beats American Bio Medica on 3 of the 5 factors compared between the two stocks.

Reliv' International (NASDAQ:RELV) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership.

Earnings & Valuation

This table compares Reliv' International and Cotinga Pharmaceuticals' top-line revenue, earnings per share and valuation.

Reliv' International has higher revenue and earnings than Cotinga Pharmaceuticals.

Profitability

This table compares Reliv' International and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Reliv' International and Cotinga Pharmaceuticals, as provided by MarketBeat.com.

Risk and Volatility

Reliv' International has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, meaning that its share price is 4,244% more volatile than the S&P 500.

Institutional and Insider Ownership

8.0% of Reliv' International shares are owned by institutional investors. 31.2% of Reliv' International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cotinga Pharmaceuticals beats Reliv' International on 5 of the 9 factors compared between the two stocks.

Cotinga Pharmaceuticals (OTCMKTS:COTQF) and Peak Pharmaceuticals (OTCMKTS:PKPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and recommmendations for Cotinga Pharmaceuticals and Peak Pharmaceuticals, as reported by MarketBeat.

Earnings & Valuation

This table compares Cotinga Pharmaceuticals and Peak Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Volatility and Risk

Cotinga Pharmaceuticals has a beta of 43.44, indicating that its share price is 4,244% more volatile than the S&P 500. Comparatively, Peak Pharmaceuticals has a beta of -0.91, indicating that its share price is 191% less volatile than the S&P 500.

Profitability

This table compares Cotinga Pharmaceuticals and Peak Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Cotinga Pharmaceuticals beats Peak Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

iCo Therapeutics (OTCMKTS:ICOTF) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares iCo Therapeutics and Cotinga Pharmaceuticals' revenue, earnings per share and valuation.

Profitability

This table compares iCo Therapeutics and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Volatility & Risk

iCo Therapeutics has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, indicating that its share price is 4,244% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for iCo Therapeutics and Cotinga Pharmaceuticals, as reported by MarketBeat.com.

Summary

Cotinga Pharmaceuticals beats iCo Therapeutics on 4 of the 5 factors compared between the two stocks.

Acura Pharmaceuticals (OTCMKTS:ACUR) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Acura Pharmaceuticals and Cotinga Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Acura Pharmaceuticals and Cotinga Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Acura Pharmaceuticals has higher revenue and earnings than Cotinga Pharmaceuticals.

Volatility & Risk

Acura Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 43.44, suggesting that its stock price is 4,244% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Acura Pharmaceuticals and Cotinga Pharmaceuticals, as provided by MarketBeat.

Summary

Cotinga Pharmaceuticals beats Acura Pharmaceuticals on 5 of the 6 factors compared between the two stocks.